A Convenient Synthesis of Novel Sugar-lactam Hybrids Using Aubé Reaction

Suresh E. Kurhade, Tanaji Mengawade, Debnath Bhuniya, Venkata P. Palle, and D. Srinivasa Reddy*

Corresponding author

Dr. D. Srinivasa Reddy Discovery Chemistry, Advinus Therapeutics Pvt. Ltd., Quantum Towers, Plot No. 9, Rajiv Gandhi Infotech Park, Phase-I, Hinjewadi, Pune, 411057, India. Tel: 91 20 6653 9600 Fax: 91 20 6653 9620 E-mail: dsrinivas.reddy@advinus.com

Supporting Information

	Page	
Experimental procedures	S-2	
References	S-18	
Copies of ¹ H & ¹³ C NMR spectra	S-19	

General:

All reagents, starting materials, and solvents (including dry solvents) were obtained from commercial suppliers and used as such without further purification. Reactions were carried out in oven-dried glassware under a positive pressure of argon unless otherwise mentioned. Column chromatography was performed on silica gel (Rankem, 100-200 mesh). Deuterated solvents (Cambridge Isotope Laboratories) for NMR spectroscopic analyses were used as received. All NMR spectra were recorded on Varion 400 MHz spectrometer. Coupling constants are measured in Hertz. All chemical shifts are quoted in ppm, relative to tetramethylsilane, using the residual solvent peak as a reference standard. Optical rotation was recorded from Rudolph autopol-V polarimeter at 589 nm (sodium D-line). Mass spectra were measured on a Agilent MSD/VL with ESI ionization. HRMS data was obtained from JEOL MS route 600H instrument. Infrared (IR) spectra were recorded on a Perkin-Elmer 100 FT-IR spectrometer.

Experimental details:



Methyl 6-deoxy-6-N-azepan-2-one-α-D-mannopyranoside (3). To the mixture of 6-Azido-6deoxy-methyl-α-D-mannopyranoside 1^{1} (0.25g, 1.14 mmol) and cyclohexanone (0.18 mL, 3.50 mmol) in dichloromethane (5 mL), BF₃.Et₂O (0.57mL, 4.57 mmol) was added drop wise under argon atmosphere at 0 °C. Reaction mixture was allowed to warm up to room temperature and stirring continued for 24 hours. The reaction mixture was diluted with diethyl ether (5 mL) and 50% aq. KOH (1 mL) was added. After stirring for additional one hour, reaction mixture was evaporated to dryness and purified by column chromatography using 30% ethyl acetate: hexane to neat ethyl acetate to get **2** and **3** in 230 mg and 36 mg respectively. Compound **2**: Mp = 89-91°C; $[\alpha]^{25}$ D = -15.6° (*c* 1, CH₃OH); IR (CHCl₃): 1071, 1099, 1623, 3368 cm⁻¹; ¹H NMR (CD₃OD, 400 MHz) δ 1.34-1.79 (series of m, 15H), 2.51-2.61 (m, 2H), 3.33 (d, *J* = 3.6 Hz, 1H), 3.36 (s, 3H), 3.49 (d, *J* = 2.4 Hz, 1H), 3.52-3.55 (m, 1H), 3.58-3.64 (m, 2H), 3.85 (d, *J* = 4.80 Hz, 1H), 3.88 (d, *J* = 4.80 Hz, 1H), 4.00 (dd, *J* = 5.6, 7.6 Hz, 1H), 4.09 (d, *J* = 5.6 Hz, 1H), 4.87 (s, 1H); ¹³C NMR (100.6 MHz, CD₃OD) δ 179.9, 110.9, 99.6, 78.5, 76.5, 71.5, 70.6, 55.3, 53.1, 50.7, 39.2, 37.5, 36.4, 30.7, 28.7, 26.0, 25.0, 24.7, 24.5; LCMS = 370.2 (M+1); HRMS (ESI): *m*/*z* calculated for C19H31NO₆Na [M + Na]⁺ 392.2049, found 392.2096. Compound **3**: [α]²⁵D = +24.4° (*c* 1, CH₃OH); IR (CHCl₃): 1610, 3392 cm⁻¹; ¹H NMR (CD₃OD, 400 MHz) δ 1.64-1.82 (m, 6H), 2.55-2.58 (m, 2H), 3.34 (s, 3H), 3.47 (t, *J* = 10 Hz, 1H), 3.55-3.62 (m, 4H), 3.66 (dd, *J* = 3.6, 9.2 Hz, 1H), 3.76-3.81 (m, 2H), 4.58 (d, *J* = 1.6 Hz, 1H). ¹³C NMR (100.6 MHz, CD₃OD) δ 179.7, 102.9, 73.3, 71.8, 71.7, 69.6, 55.3, 53.1, 51.0, 37.6, 30.8, 28.7, 24.4; MS = 290 (M+1); HRMS (ESI): *m*/*z* calculated for C13H24NO₆ [M + H]⁺290.1603, found 290.1586.

Conversion of compound **2** *to compound* **3**: The compound **2** (230 mg) was dissolved in 80% aq. acetic acid (5 mL) and stirred at 80 °C. After 24 hours, the reaction mixture was evaporated to dryness to furnish the crude product. The crude compound was purified by column chromatography using silica gel and eluted with 50% ethyl acetate: hexane to neat ethyl acetate get 170 mg of titled product **3**. Overall yield: 205 mg. (64%).

Compounds 4-11 are prepared using the analogous procedure described for the synthesis of 3.



Methyl 6-deoxy-6-*N*-pyrrolidine-2-one-α-D-mannopyranoside (4). Yield 66%. $[\alpha]^{24.8}_{D} = +28.9^{\circ}$ (*c* 1, CH₃OH); IR (CHCl₃): 1054, 1656, 3392 cm⁻¹; ¹H NMR (CD₃OD, 400 MHz) δ 2.02-2.09 (m, 2H), 2.37-2.41 (m, 2H), 3.33 (s, 3H), 3.45 (t, J = 9.2 Hz, 1H), 3.56-3.68 (m, 6H), 3.75 (dd, J = 1.2 Hz, J = 3.2 Hz, 1H), 4.58 (s, 1H); ¹³C NMR (100.6 MHz, CD₃OD) δ 178.3, 102.8, 72.6, 71.9, 71.8, 69.8, 55.2, 50.8, 45.2, 31.8, 19.2; LCMS = 262 (M+1); HRMS (ESI): m/z calculated for C₁₁H₁₉NO₆Na [M + Na]⁺ 284.1110, found 284.1101.



Methyl 6-deoxy-6-*N*-piperidine-2-one-α-D-mannopyranoside (5). Yield 64%; $[\alpha]^{23.9}_{D} = +50.9^{\circ}$ (*c* 1, CH₃OH); IR (CHCl₃): 1054, 1602, 3411 cm⁻¹; ¹H NMR (CD₃OD, 400 MHz) δ 1.77-1.86 (m, 4H), 2.34-2.40 (m, 2H), 3.31 (s, 3H), 3.46 (t, *J* = 9.60 Hz, 1H), 3.52-3.57 (m, 2H), 3.63 (d, *J* = 3.2 Hz, 1H), 3.65-3.70 (m, 3H), 3.77 (dd, *J* = 1.6, 3.2 Hz, 1H), 4.58 (d, *J* = 1.6 Hz, 1H); ¹³C NMR (100.6 MHz, CD₃OD) δ 173.3, 102.8, 72.8, 71.9, 71.8, 70.0, 55.1, 51.6, 49.9, 32.8, 24.0, 21.9; LCMS = 276(M+1); HRMS (ESI): *m*/*z* calculated for C₁₂H₂₁NO₆Na [M + Na]⁺ 298.1266, found 298.1253.



Methyl 6-deoxy-6-*N*-[1,4]oxazepan-5-one-α-D-mannopyranoside (6). Yield 52%; $[\alpha]^{25}$ D = +21.4° (*c* 1, CH₃OH); IR (CHCl₃):1491, 1619, 3392 cm⁻¹; ¹H NMR (CD₃OD, 400 MHz) δ 2.70-2.88 (m, 2H), 3.34 (s, 3H), 3.51 (t, *J* = 9.60 Hz, 1H), 3.59-3.90 (series of m, 11H), 4.59 (d, *J* = 1.60 Hz, 1H); ¹³C NMR (100.6 MHz, CD₃OD) δ 178.0, 102.9, 73.3, 71.7, 71.5, 70.9, 69.5, 65.9, 55.4, 55.1, 51.0, 41.7; LCMS = 292.0 (M+1); HRMS (ESI): *m*/*z* calculated for C12H21NO₇Na [M+Na]⁺ 314.1215, found 314.1264.



Methyl 6-deoxy-6-*N*-[1,4]thiazepan-5-one-α-D-mannopyranoside (7). Yield 57%; $[\alpha]^{23.7}_{D}$ = +18.8° (*c* 0.5, CH₃OH); IR (CHCl₃): 1425, 1623, 3369.0 cm⁻¹; ¹H NMR (CD₃OD, 400 MHz) δ 2.66-2.80 (m, 4H), 2.90-2.97 (m, 2H), 2.99 (t, *J* = 5.6 Hz, 1H), 3.34 (s, 3H), 3.34-3.50 (m, 2H), 3.58-3.68 (m, 2H), 3.77-3.84 (m, 1H), 3.91-3.95 (m, 2H), 4.60 (s, 1H); ¹³C NMR (100.6 MHz, CD₃OD) δ 177.9, 103.0, 73.3, 71.8, 71.7, 69.6, 55.3, 55.1, 51.1, 41.2, 29.8, 24.6; LCMS = 308(M+1); HRMS (ESI) : *m*/*z* calculated for C12H22NO₆S [M + H]⁺ 308.1167, found 308.1182.



Methyl 6-deoxy-6-*N*-(5*R*)-phenyl-azepan-2-one-α-D-mannopyranoside (8). Yield 40%; Mp = $63-65^{\circ}$ C (fused); [α]^{22.2}D = 4.84° (*c* 0.5, CH₃OH); IR (CHCl₃): 1619, 3412 cm⁻¹; ¹H NMR(CD₃OD, 400 MHz) δ 1.70 (q, *J* = 12.8, 1H), 1.83-1.90 (m, 1H), 1.94-2.00 (m, 1H), 2.25 (q, *J* = 12.8 Hz, 1H), 2.55 (dd, *J* = 7.2, 13.6 Hz, 1H), 2.77-2.89 (m, 2H), 3.34 (s, 3H), 3.45 (d, *J* = 14.4 Hz, 1H), 3.53-3.61 (m, 3H), 3.70-3.71 (m, 1H), 3.81-3.82 (m, 1H), 3.84 (d, *J* = 4.0 Hz, 1H), 4.08 (dd, *J* = 11.2, 3.76 Hz, 1H), 4.61 (s, 1H), 7.12-7.26 (m, 5H); ¹³C NMR (100.6 MHz, CD₃OD) δ 179.4, 147.9, 129.4 (2C), 128.0 (2C), 127.2, 103.0, 74.0, 71.8, 71.5, 69.1, 55.2, 52.7, 50.8, 49.5, 37.0, 35.9, 32.4; LCMS = 366.1 (M+1); HRMS (ESI): *m/z* calculated for C19H27NO₆ Na [M + Na]⁺388.1736, found 388.1739.



Methyl 6-deoxy-2,3,4-tri-*O*-acetyl-6-*N*-(5*R*)-phenyl-azepan-2-one- α -D-mannopyranoside. To the mixture of (8) (0.3g, 0.82 mmol), and pyridine (0.7 mL, 6.57 mmol) in dichloromethane

(5 mL), Ac₂O (0.53mL, 6.57 mmol) and DMAP (5 mg, 0.041 mmol) was added at room temperature. Reaction mixture was stirred for 16 hours. The reaction mixture was diluted with ice water (20 mL) followed by extraction using dichloromethane (3X20 mL), combined organic layer was washed with 1N HCl (2X10mL), brine (20 mL) and dried over sodium sulfate. The solvent was evaporated under reduced pressures to yield the crude product which was purified by column chromatography followed by crystallization in hot ethanol (10 mL) to furnish the title compound (160 mg); Yield 40% (after recrystallization); Mp = 192-194°C; $[\alpha]^{22.8}_{D} = 64.9^{\circ}$ (*c* 1, CH₃OH); IR (CHCl₃): 1084, 1135, 1222, 1648, 1753 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 1.75-1.93 (m, 3H), 1.94 (s, 3H), 1.99 (s, 3H), 2.01-2.08 (m, 1H), 2.11 (s, 3H), 2.62-2.68 (m, 2H), 2.72-2.82 (m, 1H), 3.35 (s, 3H), 3.59-3.72 (m, 4H), 3.96-4.10 (m, 1H), 4.62 (s, 1H), 5.16-5.21 (m, 2H), 5.28-5.31 (m, 1H), 7.19-7.25 (m, 3H), 7.27-7.32 (m, 2H); ¹³C NMR (100.6 MHz, CDCl₃) δ 175.9, 170.6, 170.2, 170.1, 146.5, 128.9 (2C), 127.0 (2C), 126.8, 98.8, 71.1, 70.0, 69.5, 67.2, 55.3, 50.6, 48.6, 48.5, 26.9, 36.8, 30.3, 21.1, 20.9, 20.9. LCMS = 492.3 (M+1).



Methyl 6-deoxy-6-*N*-(5*R*)-tert-butyl)azepan-2-one-α-D-mannopyranoside (9). Yield 52%; Mp = 159-161°C; $[\alpha]^{22.6}$ D = 26.2° (*c* 0.5, CH₃OH); IR (CHCl₃): 1457.7, 1618.6, 3392 cm⁻¹; ¹H NMR (CD₃OD, 400 MHz) δ 0.89 (s, 9H), 1.21-1.33 (m, 3H), 1.55 (m, 2H), 1.80-1.96 (m, 1H), 2.00-2.06 (m, 1H), 2.49 (dd, *J* = 7.2, 13.2 Hz, 1H), 2.61 (t, *J* = 12 Hz, 1H), 3.33 (s, 3H), 3.47-3.68 (m, 4H), 3.76-3.78 (m, 1H), 3.89 (dd, *J* = 4.8, 14.4 Hz, 1H), 4.60 (d, *J* = 1.2 Hz, 1H); ¹³C NMR (100.6 MHz, CD₃OD) 179.7, 103.0, 73.7, 71.8, 71.6, 69.3, 55.2, 52.8, 52.7, 50.7, 36.8, 33.8, 29.9, 28.0 (3-C), 25.3; LCMS = 346 (M+1); HRMS (ESI) : *m*/*z* calculated for C17H32NO₆ [M+H]⁺ 346.2229, found 346.2201.



Methyl 6-deoxy-6-*N*-[1,4]diazepane-1-carboxylic acid benzyl ester azepan-5-one-α-Dmannopyranoside (10). Yield 40%; $[\alpha]^{23.6}D = +25.6^{\circ}$ (*c* 1, CH₃OH); IR (CHCl₃); 1241, 1431, 1626, 1697, 3392 cm⁻¹; ¹H NMR (CD₃OD, 400 MHz) δ 2.69-2.73 (m, 2H), 3.32 (s, 3H), 3.34-3.35 (m, 1H), 3.44-3.54 (m, 2H), 3.58-3.69 (m, 5H), 3.76 (dd, *J* = 2.0, 3.6 Hz, 1H), 3.80-3.87 (m, 3H), 4.59 (s, 1H), 5.13 (s, 2H), 7.30-7.35 (m, 5H); ¹³C NMR (100.6 MHz, CD₃OD) δ 177.5, 157.0, 137.9, 129.5 (2C), 129.2, 129.0 (2C), 102.9, 73.3, 71.7, 71.5, 69.4, 68.6, 55.3, 53.5, 51.1, 47.8, 42.6, 39.5; LCMS = 425 (M+1); HRMS (ESI) : *m*/*z* calculated for C₂₀H₂₉N₂O₈ [M + H]⁺ 425.1924, found 425.1909.



Methyl-6-deoxy-6-*N*-1,4-dihydro-2H-isoquinolin-3-one-α-D-mannopyranoside (11). Yield = 10%; $[\alpha]^{23.3}D = +37.5^{\circ}$ (*c* 1, CH₃OH); IR (CHCl₃): 1377, 1668, 3392 cm⁻¹; ¹H NMR (CD₃OD, 400 MHz) δ 3.08 (s, 3H), 3.46-3.50 (m, 1H), 3.55-3.75(m, 5H), 3.97 (d, *J* = 12 Hz, 1H), 4.55 (d, *J* = 1.2 Hz, 1H), 4.71 (d, *J* = 5.6 Hz, 2H), 7.18-7.25 (m, 5H); ¹³C NMR (100.6 MHz, CD₃OD) δ 172.8, 133.9, 133.4, 128.5, 127.9, 127.7, 126.2, 102.7, 72.9, 72.0, 71.9, 70.1, 55.0, 54.1, 38.5, 30.7; LCMS = 324 (M+1).

Compounds 20, 21, 22, 23, 25 and 26 are prepared using the analogous procedure (1st step) described for the synthesis of 3.



Methyl 6-deoxy-6-*N*-piperidine-2-one-α-D-glucopyranoside (20).

Yield 66%; Mp = 197-199°C; $[\alpha]^{24.8} D = +69.6^{\circ}$ (*c* 1, CH₃OH); IR (CHCl₃): 1048, 1602, 3338 cm⁻¹; ¹H NMR (DMSO-d6, 400 MHz) δ 1.64-1.72 (m, 4H), 1.98- 2.60 (m, 3H), 2.88 (ddd, *J* = 4.4, 9.6, 5.5 Hz, 1H), 3.12- 3.20 (m, 3H), 3.21 (s, 3H), 3.92-3.42 (m, 1H), 3.52-3.57 (m, 1H), 3.71 (dd, *J* = 1.6, 14.0 Hz, 1H), 4.50 (d, *J* = 4.0 Hz, 1H), 4.75 (br s, 1H), 4.82 (br s, 1H), 5.01 (d, *J* = 4.4 Hz, 1H); ¹³C NMR (100.6 MHz, DMSO-d-6) δ 168.9, 99.6, 72.7, 72.2, 71.8, 70.1, 54.1, 49.3, 48.1, 31.8, 22.8, 20.8; LCMS = 276.1 (M+1); HRMS (ESI) : *m*/*z* calculated for C₁₂H₂₂NO₆ [M+H]⁺ 276.1447, found 276.1434.



1-((2R,3S,4R)-3, 4-Dihydroxy-tetrahydro-pyran-2-ylmethyl)-piperidin-2-one (21).

Yield 65%; $[\alpha]^{23.7}_{D} = -16.78^{\circ}$ (*c* 1, CH₃OH); IR (CHCl₃): 1089, 1608, 3365 cm⁻¹; ¹H NMR (CD₃OD, 400 MHz) δ 1.50-1.61 (m, 1H), 1.79 (t, *J* = 2.8 Hz, 4H), 1.87 (dd, J = 5.6, 13.2 Hz, 1H), 2.34-2.42 (m, 2H), 2.96 (t, *J* = 7.2, 1H), 3.24-3.43 (m, 3H), 3.50-3.55 (m, 3H), 3.78 (dd, *J* = 8.4, 14.8 Hz, 1H), 3.84-3.90 (m, 1H); ¹³C NMR (100.6 MHz, CD₃OD) δ 173.6, 81.1, 74.9, 73.0, 66.8, 51.4, 50.0, 35.0, 32.7, 23.9, 21.9; LCMS = 230.3 (M+1); HRMS (ESI): *m/z* calculated for C₁₁H₂₀NO₄[M + H]⁺ 230.1392, found 230.1390.



1-((2*R***,3***S***)-3-Hydroxy-tetrahydro-pyran-2-ylmethyl)-piperidin-2-one (22).** Yield 60%; $[\alpha]^{24.2}$ D = -35.8° (*c* 1, CH₃OH); IR (CHCl₃): 1092, 1617, 3369 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 1.38-1.50 (m, 2H), 1.56-1.68 (m, 2H), 1.74-1.84 (m, 4H), 2.06-2.12 (m, 1H), 2.42-2.48 (m, 2H), 2.90 (d, *J* = 14.4 Hz, 1H), 3.12-3.31 (m, 3H), 3.64-3.72 (m, 1H), 3.84-3.86 (m, 1H), 4.43 (d, *J* = 14.4 Hz, 1H), 5.20 (br s, 1H); ¹³C NMR (100.6 MHz, CDCl₃) δ 172.3, 83.8, 68.5, 66.4, 51.2, 49.2, 32.1, 31.1, 26.0, 23.4, 21.4; LCMS = 214.2 (M+1); HRMS (ESI): *m/z* calculated for C₁₁H₂₀NO₃ [M + H]⁺ 214.1443, found 214.1456.



6-*N*-(**piperidine-2-one**)-**3**-*O*-**benzyl-6**-**deoxy-1**, **2**-*O*-**isopropylidene**-α-**D**-**glucofuranoside** (**23**). To minimize side product (**VI**) only 3 equivalents of BF₃·Et₂O was used. Yield 52%; $[α]^{24.6} D = -2.16^{\circ}$ (*c* 1, CH₃OH); IR (CHCl₃): 1074, 1614, 3287 cm⁻¹; ¹H NMR (CD₃OD, 400 MHz) δ 1.29 (s, 3H), 1.44 (s, 3H), 1.76-1.84 (m, 4H), 2.36 (t, *J* = 8.0 Hz, 2H), 3.31-3.38 (m, 3H), 3.49-3.53 (m, 1H), 3.80 (dd, *J* = 3.2, 14.4 Hz, 1H), 3.96 (dd, *J* = 2.8, 8.8 Hz, 1H), 4.03 (d, *J* = 3.2 Hz, 1H), 4.18 (ddd, *J* = 3.2 , 8.8, 12.0 Hz, 1H), 4.60-4.69 (m, 2H), 5.86 (d, *J* = 3.2 Hz, 1H), 7.27-7.38 (m, 5H); ¹³C NMR (100.6 MHz, CD₃OD) δ 174.1, 139.3, 129.3 (2C), 129.0 (2C), 128.8, 112.7, 106.6, 83.3, 83.0, 82.7, 73.3, 68.0, 53.7, 51.3, 32.8, 27.1, 26.4, 24.0, 21.8; LCMS = 392.3 (M+1); HRMS (ESI): *m/z* calculated for C₂₁H₃₀NO₆[M+H]⁺ 392.2073, found 392.2043.

Along with 23, other compound VI (13%) was also isolated and the tentatative structure is shown below. Tentative structure assigned as drawn below for the minor product based on following spectral data.



Yield 13%; IR (CHCl₃): 1078, 1615, 3306 cm⁻¹; ¹H NMR (CD₃OD, 400 MHz) δ 0.82-0.94 (m, 4H), 1.69-1.94 (m, 5H), 2.18-2.24 (m, 1H), 2.40-2.44 (m, 2H), 3.01-3.04 (m, 1H), 3.32-3.35 (m, 1H), 3.48-3.57 (m, 3H), 3.78 (dd, *J* = 1.2, 14.4 Hz, 1H), 4.02 (dd, *J* = 2.8, 9.2 Hz, 1H), 4.10-4.1.5 (m, 2H), 4.68 (q, *J* = 15.2 Hz, 2H), 5.34 (br s, 1H), 5.85 (d, *J* = 3.6 Hz, 1H), 7.26-7.38 (m, 5H); ¹³C NMR(100.6 MHz, CD₃OD) δ 173.9, 138.2, 128.7 (2C), 128.1 (2C), 128.0, 121.7, 105.2, 83.2, 82.0, 81.1, 73.1, 69.0, 54.1, 50.9, 37.4, 36.8, 32.3, 23.8, 23.4, 23.2, 21.2; LCMS = 418.0 (M+1).



Methyl 6-deoxy-6-*N*-piperidine-2-one-α-D-galctopyranoside (25).

The compound **25** was synthesized by following the analogous procedure described for the synthesis of **20**, However, during hydrolysis (2nd step) excess of aq. 50% KOH (for 180 mg reaction 1.5 mL) was used and stirred for 6 hours. Yield 51%; $[\alpha]^{24.4}D = +2.68^{\circ}$ (*c* 1, CH₃OH); IR (CHCl₃): 1048, 1216, 1618, 3620 cm⁻¹; ¹H NMR (CD₃OD, 400 MHz) δ 1.78-1.84 (m, 4H), 2.35 (t, *J* = 6.0 Hz, 2H), 3.20 (dd, *J* = 8.8, 13.6 Hz, 1H), 3.34 (s, 3H), 3.36-3.44 (m, 1H), 3.56-3.64 (m, 1H), 3.67-3.77 (m, 3H), 3.85 (dd, *J* = 4.8, 14.0 Hz, 1H), 4.01 (dd, *J* = 4.8, 8.4 Hz, 1H), 4.68 (d, *J* = 3.6, 1H); ¹³C NMR (100.6 MHz, CD₃OD) δ 172.9, 101.4, 71.2, 71.1, 69.9, 69.6, 55.4, 51.4, 50.0, 32.8, 24.1, 22.0; LCMS = 276.1 (M+1); HRMS (ESI): *m/z* calculated for C_{12H21}NO₆Na [M+Na]⁺ 298.1266, found 298.1260.



5-*N*-(**piperidine-2-one**)-**3**-*O*-benzyl-**5**-deoxy-**1**, **2**-*O*-isopropylidene-α-D-glucofuranoside (**26**). To minimize side product **VII** only 3 equivalents of BF₃·Et₂O was used. Yield 52%; $[α]^{23.2}D = -8.98^{\circ}$ (*c* 1, CH₃OH); IR (CHCl₃): 1163, 1496, 3390 cm⁻¹; ¹H NMR (CD₃OD, 400 MHz) δ 1.30 (s, 3H), 1.44 (s, 3H), 1.71-1.80 (m, 4H), 2.35 (t, *J* = 6.4 Hz, 2H), 3.34-3.40 (m, 1H), 3.46-3.52 (m, 2H), 3.58 (dd, *J* = 2.8, 11.2 Hz, 1H), 3.70-3.77 (m, 1H), 3.93 (bs, 1H), 4.49-4.58 (m, 2H), 4.73 (d, *J* = 11.2 Hz, 1H), 4.77 (d, *J* = 3.6 Hz, 1H), 5.86 (d, *J* = 4.0 Hz, 1H), 7.29-7.39 (m, 5H); ¹³C NMR (100.6 MHz, CD₃OD) δ 173.6, 138.7, 129.4 (2C), 129.4, (2C), 129.0, 112.7, 105.8, 83.1, 82.6, 77.3, 72.6, 60.7, 33.4, 27.0, 26.4, 24.2, 23.9, 21.4 (2C); LCMS = 392.3 (M+1). Along with **26**, other compound **VII** (21%) also isolated and the tentative structure is shown below. Tentative structure assigned as drawn below for the minor product based on following spectral data.



[α]^{23.3}_D = -4.00° (*c* 0.5, CH₃OH); IR (CHCl₃): 1336, 1120, 1615, 3399cm⁻¹; ¹H NMR (CD₃OD, 400 MHz) δ 1.64-1.92 (series of m, 13H), 2.36 (t, *J* = 6.4 Hz, 2H), 3.37-3.39 (m, 1H), 3.46-3.56 (m, 1H), 3.57 (dd, *J* = 2.8, 11.2 Hz, 1H), 3.66-3.77 (m, 1H), 3.95 (d, *J* = 2.4 Hz, 1H), 4.49-4.58 (m, 2H), 4.69-4.74 (m, 2H), 5.83 (d, *J* = 4.0 Hz, 1H), 7.28-7.39 (m, 5H); ¹³C NMR(100.6 MHz, CD₃OD) δ 173.5, 138.7, 129.4 (2C), 129.3 (2C), 129.0, 122.3, 105.5, 83.2, 82.6, 77.4, 72.6, 60.8, 49.8, 37.8, 37.2, 33.4, 24.4 (2C), 23.9, 23.8, 21.4; LCMS = 418.3 (M+1).

Synthesis of deoxy sugar azides:



Toluene-4-sulfonic acid (2*R*,3*S*,4*R*)-3,4-dihydroxy-tetrahydro-pyran-2-ylmethyl ester (C).² To a solution of (2*R*, 3*S*, 4*R*)-2-ethyl-tetrahydro-pyran-3, 4-diol³ (3.0g, 20.8 mmol) in pyridine (20 mL), *p*-tolunesulfonyl chloride (4.3 g, 22.9 mmol) was added and reaction mixture allowed to stir for overnight at room temperature. Reaction mixture was diluted with cold water and neutralized with 1N HCl (~pH 6) followed by extraction with dichloromethane (3X30 mL). Combined organic layer was washed with brine and dried over sodium sulfate. After evaporation of the solvent furnished the desired compound C (3.0g). Yield 48%; IR (CHCl₃): 669, 771, 1215, 3019 cm⁻¹; ¹H NMR (CD₃OD, 400 MHz) δ 1.46-1.55 (m, 1H), 1.85 (dd, *J* = 4.8, 12.8 Hz, 1H), 1.98 (d, *J* = 9.6 Hz, 1H), 2.45 (s, 3H), 3.05 (t, *J* = 9.2 Hz, 1H), 3.22 (m, 1H), 3.35-3.47 (m, 1H), 3.80 (dd, *J* = 5.2, 10.8 Hz, 1H), 4.10 (dd, *J* = 5.2, 10.8 Hz, 1H), 4.30 (dd, *J* = 1.2, 10.4 Hz, 1H), 7.43 (d, *J* = 8.0 Hz, 2H), 7.78 (d, *J* = 8.4 Hz, 2H); ¹³C NMR (100.6 MHz, CD₃OD) δ 146.4, 134.4, 130.9 (2C), 129.0 (2C), 79.4, 73.8, 72.9, 71.3, 66.5, 34.8, 21.5; LCMS = 303.0 (M+1).



(2R,3S,4R)-2-Azidomethyl-tetrahydro-pyran-3, 4-diol (13).

To a solution C (800 mg, 2.64 mmol) in DMF (10 mL), sodium azide (1.80 g, 26.4 mmol) was added and the reaction mixture was allowed to stir for 18 hours at 80 0 C. Reaction mixture was diluted with cold water and extracted with dichloromethane (3X30 mL). Combined organic layer was washed with brine, dried over sodium sulfate and evaporation of solvent resulted in compound **13** (300 mg). Yield 66%; IR (CHCl₃): 2099, 3400cm⁻¹; ¹H NMR (CD₃OD, 400 MHz) δ 155-1.65 (m, 1H), 1.88-1.93 (m, 1H), 3.14 (t, *J* = 9.3 Hz, 1H), 3.21-3.26 (m, 1H), 3.37 (dd, *J* = 6.9, 13.2 Hz, 1H), 3.42-3.53 (m, 3H), 3.90-3.94 (m, . 1H); ¹³C NMR (100.6 MHz, CD₃OD) δ 81.1, 74.1, 73.8, 66.6, 53.0, 35.0; LCMS = 191.1 (M+18).



Toluene-4-sulfonic acid (2R,3S)-3-hydroxy-tetrahydro-pyran-2-ylmethyl ester⁴ (E).

To a solution of ((2R,3S)-2-Hydroxymethyl-tetrahydro-pyran-3-ol⁵ (2.0 g, 15.15 mmol) in pyridine (20 mL), *p*-Tolunesulfonyl chloride (3.45 g, 18.18 mmol) was added and reaction mixture allowed to stir for overnight at room temperature. Reaction mixture was diluted with ice water and neutralized with 1N HCl to pH 6 followed by extraction with dichloromethane (3X30 mL), combined organic layer washed with brine and dried with sodium sulfate. After evaporation of solvent furnished the title compound **E** (3.1g). Yield 70%; IR (CHCl₃): 669, 771, 1216, 3019 cm⁻¹; ¹H NMR (CD₃OD, 400 MHz) δ 1.34-1.41 (m, 2H), 1.55-1.62 (m, 2H), 2.01-2.05 (m, 1H), 2.45 (s, 3H), 3.15-3.19 (m, 1H), 3.22-3.26 (m, 1H), 3.76-4.08 (m, 1H), 4.06 (dd, *J* = 6.0, 10.4 Hz, 1H), 4.28 (dd, *J* = 1.6, 10.8 Hz, 1H), 7.43 (d, *J* = 8.0 Hz, 2H), 7.78 (d, *J* = 8.0 Hz, 2H); ¹³C NMR (100.6 MHz, CD₃OD) δ 146.3, 134.3, 130.9 (2C), 129.1 (2C), 81.4, 71.5, 68.5, 66.7, 33.6, 26.3, 21.6; LCMS = 287.0 (M+1).



(2R, 3S)-2-Azidomethyl-tetrahydro-pyran-3-ol (14).

To a solution of **E** (1.0 g, 3.49 mmol) in DMF (10 mL), sodium azide (2.49 g, 34.9 mmol) was added and reaction mixture allowed to stir for 18 hours at 80 °C. Reaction mixture was diluted with ice water and extraction with dichloromethane (3X30 mL), combined organic layer washed with brine, dried over sodium sulfate, and evaporation of solvent resulted in **14** (480 mg). Yield 86%. IR (CHCl₃): 2099, 3400 cm⁻¹; ¹H NMR (CD₃OD, 400 MHz) δ 1.36-1.46 (m, 1H), 1.62-1.70 (m, 2H), 2.05-2.08 (m, 1H), 3.16-3.20 (m, 1H), 3.32-3.38 (m, 3H), 3.48 (d, *J* = 13.2 Hz, 1H), 3.86-3.92 (m, 1H); ¹³C NMR (100.6 MHz, CD₃OD) δ 83.1, 68.6, 68.0, 53.1, 33.5, 26.5; LCMS = 175.2 (M+18).



(2R, 3S)-2-Azidomethyl-3-methoxy-tetrahydro-pyran (19).

To a solution of (14) (200 mg, 1.25 mmol) in anhydrous THF (5 mL), sodium hydride (60% in mineral oil, 90 mg, 1.88 mmol) was added at 0 °C and reaction mixture allowed to stir for one hour at room temperature. Reaction mixture was cooled again to 0 °C and methyl iodide (0.16 mL, 3.7 mmol) added and stirring continued for another hour at room temperature. Reaction mixture was diluted with ice water and extraction with dichloromethane (3X15 mL). The combined organic layer was washed with brine, dried over sodium sulfate and evaporation of solvent led to compound **19** (185 mg). Yield 85%; IR (CHCl₃): 1099, 1432, 2099 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 1.23-1.33 (m, 2H), 1.61-1.70 (m, 2H), 2.30-2.33 (m, 1H), 3.05-3.09 (m, 1H), 3.24-28 (m, 1H), 3.35 (s, 3H), 3.37-3.43 (m, 1H), 3.52- 3.55 (d, *J* = 12.8 Hz, 1H), 3.96 (dd, *J* = 4.4, 13.6 Hz, 1H); ¹³C NMR (100.6 MHz, CDCl₃) δ 80.0, 75.9, 67.9, 56.3, 52.3, 28.3, 25.1.

Unsuccessful efforts toward alternate synthesis of sugar lacatam 3.



Alternate route to the synthesis of sugar-lacatm 3.





Methyl 6-deoxy-6-iodo-2, 3, 4-tri-*O*-benzyl-α-D-mannopyranoside (III).⁶ To a solution of 2, 3, 4-Tri-*O*-benzyl-α-methyl-D-mannopyranoside⁷ (2.0 g, 4.30 mmol) in pyridine (20 mL), *p*-tolunesulfonyl chloride (2.0 g, 4.31 mmol) was added and the reaction mixture allowed to stir for 6 hours at room temperature. Reaction mixture was diluted with ice water and neutralized with 1N HCl (~ pH 6) followed by extraction with dichloromethane (3X30 mL). The combined organic layer washed with brine, dried over sodium sulfate and evaporation of solvent resulted in crude product, which was purified by column chromatography (10%EtOAc:Hexane) to furnish the tosylate (2.4 g). Yield 90%; $[\alpha]^{25.8}$ D = +15.6° (*c* 1, CH₃OH); IR (CHCl₃ 1215, 3019 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) 2.39 (s, 3H), 3.24(s, 3H), 3, 74-3.82 (m, 4H), 4.21-4.28 (m, 2H), 4.45 (d, *J* =11.2 Hz, 1H), 4.56 (s, 2H), 4.64-4.67 (m, 3H), 4.66 (d, *J* =10.8 Hz, 1H), 7.18 (s, 2H), 7.25-7.30 (m, 15H), 7.77(d, *J* = 6.4 Hz, 2H); ¹³C NMR (100.6 MHz, CDCl₃) δ 144.9, 138.5, 138.4, 138.3, 133.2, 130.0 (2C), 128.6 (4C), 128.3 (2C), 128.2 (2C), 128.1 (2C), 128.0 (2C), 128.0 (2C), 127.9, 127.9 (2C), 99.1, 80.3, 75.3, 74.5, 74.3, 72.9, 72.3, 70.2, 69.5, 55.1, 21.9; LCMS = 635.9 (M+18);

To a solution of above tosylate (2.0 g, 3.23 mmol) in toluene (50 mL), HMPA (5.63 ml, 32.36 mmol) and lithium iodide (4.3 g, 32.36 mmol) was added and reaction mixture was refluxed for 24 hours. Reaction mixture was diluted with ice water and extraction with ethyl acetate (3X30 mL), combined organic layer washed with aq. sodium thiosulfate, brine and dried with sodium sulfate. The crude product obtained after evaporation of solvent was purified using 10% EtoAc: hexane to furnish the title compound III (1.6 g). Yield 89%; $[\alpha]^{24.8}D = +22.4^{\circ}$ (*c* 1, CH₃OH); IR (CHCl₃): 669, 771, 1215, 3019 cm⁻¹; ¹H NMR (CD₃OD, 400 MHz) δ 3.29-3.31 (m, 1H), 3.36 (s, 3H), 3.49-3.57 (m, 2H), 3.74-3.78 (m, 2H), 3.88 (dd, *J* = 7.0, 2.0 Hz, 1H), 4.59 (s, 2H), 4.65-4.68 (m, 1H), 4.72-4.76 (m, 3H), 4.98 (d, *J* = 10.8 Hz, 1H), 7.20-7.30 (m, 15H); ¹³C NMR (100.6 MHz, CD₃OD) δ 138.5, 138.5, 138.4, 128.7 (2C), 128.7 (2C), 128.6 (2C), 128.3 (2C), 128.1 (2C), 127.9 (2C), 127.9 (2C), 99.3, 80.2, 78.8, 75.7, 74.8, 73.0, 72.3, 71.7, 55.3, 7.4; LCMS = 592 (M+18);



6-Deoxyhex-eno-pyranoside(IV) and Methyl 6-deoxy-2,3,4-tri-O-benzyl-6-*N***-azepan-2-one-\alpha-D-mannopyranoside (V).** To a solution of caprolactam (395 mg, 3.48 mmol) in dry THF (5 mL), KHMDS (0.5 M in toluene 7.0 ml, 3.48 mmol) was added at 0 °C followed by 18-crown-6 (197 mg, 0.87 mmol) and the reaction mixture was allowed to stir at room temperature for 3 hrs. After that reaction mixture was cooled to 0°C and a solution of III (1.0g, 1.74 mmol) in THF (10ml) was added. After stirring for two hours at room temperature, the reaction mixture was heated to 50 °C for 12 hours. Reaction was quenched with saturated aq.NH₄Cl (10 mL) at room temperature. Reaction mixture was extracted with ethyl acetate (3X25 mL), washed the combined organic layer with brine and dried over sodium sulfate. The crude product obtained after evaporation of solvent was purified using preparative HPLC to furnish compound **IV** (200 mg, 26%) and **V**, (60 mg, 6%).

Spectral data for **IV.** $[\alpha]^{25.8}$ _D = -18.2° (*c* 1, CH₃OH); IR (CHCl₃): 669, 1215, 3019 cm⁻¹; ¹H NMR (CD₃OD, 400 MHz) δ 3.40 (s, 3H), 3.83-3.86 (m, 1H), 3.88 (d, *J* = 2.8 Hz, 1H), 4.34 (d, *J* = 8.4 Hz, 1H), 4.63- 4.80 (m, 9H), 7.25-7.36 (m, 15H); ¹³C NMR (100.6 MHz, CD₃OD) δ 154.9, 138.7, 138.4, 138.4, 128.6 (2C), 128.5, 128.5, 128.4 (2C), 128.1(2C), 128.0, 128.0, 127.9 (2C), 127.8, 127.8, 127.7, 100.9, 96.9, 78.8, 76.9, 75.8, 73.8, 73.4, 73.1, 55.6; LCMS = 464.0 (M+18); HPLC Purity (%) = 99.2; Spectral data for **V:**- $[\alpha]^{25.8}$ _D = -1.04°(*c* 1, CH₃OH); IR (CHCl₃): 669, 771, 1215, 1658cm⁻¹; ¹H NMR (CD₃OD, 400 MHz) δ 1.65 (s, 6H), 2.50-2.54 (m, 2H), 3.27 (s, 3H), 3.47-3.49 (m, 2H), 3.56 (dd, *J* = 7.6, 13.9 Hz, 1H), 3.68 (t, *J* = 9.3 Hz, 1H), 3.58-3.78 (m, 2H), 3.87-3.94 (m, 2H), 4.60 (s, 2H), 4.67-4.77 (m, 4H), 4.90 (d, *J* = 10.5 Hz, 1H), 7.18-7.40 (m, 15H); ¹³C NMR (100.6 MHz, CD₃OD) δ 181.3, 143.8, 143.5, 143.4, 133.5 (2C), 133.4, 133.4, 133.2 (2C), 133.1 (2C), 133.0 (2C), 132.9 (2C), 132.8, 132.7, 132.6, 104.1, 85.2, 82.5, 82.4, 82.2, 81.9, 81.4, 79.8, 59.9, 56.3, 54.4, 42.5, 35.1, 33.4, 28.6; LCMS = 560.4 (M+1); HPLC Purity (%) = 98.4; HRMS (ESI): *m*/*z* calculated for C₃₄H₄₁NO₆Na [M + Na]⁺ 582.2831 found 582.2826.



Methyl 6-deoxy-6-*N*-azepan-2-one- α -D-mannopyranoside (3). 10% dry Pd/C (10 mg) was added to the solution V (50 mg, 0.08 mmol) in EtOAc:ethanol (3:1) mixture.Reaction mixture was stirred under hydrogen atmosphere for 18 hours at room temperature and filtered through a celite pad. Evaporation of solvent furnished the title compound 3 (20 mg) in 77% yield. The spectral data (¹H and ¹³C) is compared with that of 3 prepared using Aube reaction and found that they are identical.

References:

- Wu, X. J.; Tang, X.; Xian, M.; Braunschweiger, P. G.; Wang, P. G. Bioorg. Med. Chem. 2002, 10, 2303.
- Tamaruya, Y.; Suzuki, M.; Kamura.G., Kanai, M.; Hama, K.; Shimizu, K.; Aoki, J.; Arai, H.; Shibasaki, M. Angew. Chem., Int. Ed. 2004, 43, 2834.
- 3. Magnani, J. L.; Patton, J. T. Jr.; Sarkar, A. K. WO Patent, WO021721, 2007.
- 4. Delgado, M.; Martin, J. D. J. Org. Chem. 1999, 64, 4798.
- 5. Nicolaou, K. C.; Hwang, C.-K.; Marron, B. E.; DeFrces, S.; Couladouro, E. A.; Abe, Y.; Carrol, P. J.; Snyder, J. P. *J. Am. Chem. Soc.*, 1990, **112**, 3040.
- 6. Skaanderup, P. R.; L.; Madsen, R. J. Org. Chem. 2003, 68, 2115.
- El-Badri, M. H.; Willenbring, D.; Tantillo, D. J.; Gerva-Hague, J. J. Org. Chem. 2007, 72, 4663.













S-24





























S-38







